Synthesis, Spectroscopic Characterization and Molecular Docking Studies of 2-Butyl-4-Chloro-5-Formylimidazole Thiosemicarbazone Cobalt (II) Complex by Sreenath, Reddy, A. et al.
259
MOSM2018 November 15–17Yekaterinburg, Russia
DR-55.  SYNTHESIS,  SPECTROSCOPIC  CHARACTERIZATION  AND  MOLECULAR
DOCKING  STUDIES  OF  2-BUTYL-4-CHLORO-5-FORMYLIMIDAZOLE
THIOSEMICARBAZONE  COBALT  (II)  COMPLEX
A. Sreenath Reddy1,  L. Sivarama Krishna2,  Vishnu Nayak Badavath3,  G. Sravya4,
N. Bakthavatchala Reddy4,  G. V. Zyryanov4, 5
1 State Key Laboratory of Oil and Gas Reservoir Geology and Exploitation,
Southwest Petroleum University, Chengdu, Xindu, 610500, PR China
2 Chemical Technology, Faculty of Sciences, Chulalongkorn University,
Bangkok, 10330, Thailand
3 Department of Microbiology, Faculty of Medicine, Chulalongkorn University,
Bangkok, 10330, Thailand
4 Ural Federal University of the first President of Russia B. N. Yeltsin,
Mira St., 19, Yekaterinburg, 620002, Russia
5 I. Ya. Postovsky Institute of Organic Synthesis UB RAS,
S. Kovalevskoy/Akademicheskaya St., 20/22, Yekaterinburg, 620990, Russia
E-mail: drreddyaabaka@yahoo.com
A novel 2-Butyl-4-chloro-5-formylimidazole thiosemicarbazone cobalt (II) complex is synthesized and
characterized by using spectroscopic techniques like elemental analysis, FT-IR, HRMS, electronic spectral
analysis and Powder-X-ray diffraction. The Co (II) complex is found to be highly efficient in inhibiting
the growth of human pathogens like S. aureus, B. megaterium with MIC value 12,0 g/mL whose inhibition
zones are almost comparable with the standard antibiotic. The synthesized complex well occupy in the active
site of -ketoacyl-acyl carrier protein synthase III enzyme (PDB: 1MZS), in consists of catalytic triad and
adenine-binding site, so the designed compounds are promising for to treat bacterial infection.
